Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves 1st Non-Opioid Pain Medicine in 20 Years
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
type 2 diabetes, chronic kidney disease and FDA
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes
Doctors already use Ozempic to manage type 2 diabetes and reduce the risk of heart disease in patients with diabetes. This move, as reported by The Times, was based on research sh
FDA, Axsome and migraine
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Axsome Therapeutics announces FDA approval of Symbravo
Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in
FDA approves new migraine treatment SYMBRAVO
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®,
FDA upgrades recall of Lay's potato chips
Broccoli Recall Update as FDA Sets Highest Risk Level Over Bacteria Fears
Broccoli florets sold in Walmart stores across 20 states that were recalled over bacterial contamination fears have been given the U.S. Food and Drug Administration (FDA)'s highest risk level.
Lay's potato chips recall upgraded to FDA's most serious level. Is Ohio affected?
The FDA elevated Lay's Classic Potato Chips to the highest risk level. Here what to know, and whether the recall impacts Ohio.
FDA reclassifies Lay’s potato chips recall to the highest risk level, warning the chips could cause ‘serious adverse health consequences or death’
The FDA has raised the risk level on a recall of Lay’s potato chips to the highest level, warning the recalled product could cause death. The chips were originally recalled last month for containing undeclared milk.
13h
US FDA Identifies Cybersecurity Risks in Certain Patient Monitors
(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks ...
2d
on MSN
Trump admin's FDA withdraws proposed federal rule to ban menthol cigarettes
Trump's FDA moved to squash a proposed rule to ban menthol cigarettes just one day after the president was sworn in, angering ...
Opinion
Williamsport Sun-Gazette
1h
Opinion
What other newspapers are saying: Pharmacy benefit practices must be reformed
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
Korea Joongang Daily on MSN
3h
Celltrion's Actemra biosimilar gets FDA approval
Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Popular topics
# FDA
Related topics
FDA
recall
Journavx
Vertex Pharmaceuticals
Frito-Lay
Feedback